Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013–2020
Kevin Meesters , Manish Sadarangani , Stephen A. Clark , Ray Borrow , Raymond S.W. Tsang , Nicole Le Saux , Scott A. Halperin , Taj Jadavji , Shaun K. Morris , Julie A. Bettinger , For the members of the Canadian Immunization Monitoring Program Active (IMPACT)
{"title":"Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013–2020","authors":"Kevin Meesters , Manish Sadarangani , Stephen A. Clark , Ray Borrow , Raymond S.W. Tsang , Nicole Le Saux , Scott A. Halperin , Taj Jadavji , Shaun K. Morris , Julie A. Bettinger , For the members of the Canadian Immunization Monitoring Program Active (IMPACT)","doi":"10.1016/j.vaccine.2025.127030","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Invasive meningococcal disease, caused by <em>Neisseria meningitidis,</em> remains a significant health threat. This study examined the genetic diversity of serogroup B (NmB) organisms and assessed the potential coverage offered by the MenB-FHbp vaccine, licensed for individuals aged 10–25 years. NmB vaccines have not yet been incorporated into most routine immunization programs in Canada, with the exception of campaigns to deal with specific outbreaks and targeted vaccination efforts for at-risk groups.</div></div><div><h3>Methods</h3><div>From 2013 to 2020, NmB strains causing invasive meningococcal disease were collected through the Canadian Immunization Monitoring Program ACTive surveillance network. Each isolate underwent analysis to determine clonal complex (CC) and factor-H binding protein peptide (fHbp), and fHbp surface expression using the Meningococcal Antigen Surface Expression (MEASURE) assay.</div></div><div><h3>Results</h3><div>Of 119 isolates analyzed, 118 coded for full-length fHbp. CC-269 (48 isolates) and CC-41/44 (42 isolates) represented 75.6 % of all isolates. fHbp peptide 15 was the most prevalent peptide up until 2015 (47.4–53.9 %) but declined to 0–22.1 % afterwards. Median fHbp surface expression overall was 4270 MFI (IQR 2132–14,462). Peptides 15 and 210 (both CC-269) had the highest fHbp surface expression: peptide 15 (median: 18,446, IQR: 14,462–22,170) and peptide 210 (median: 28,306, IQR 24,935–31,678). Notably, 90.8 % of isolates had fHbp surface expression at a level associated with MenB-FHbp protection.</div></div><div><h3>Conclusion</h3><div>CC-269 and CC-41/44 predominated in 2013–2020. Notably, peptide 15, the most prevalent until 2015, declined significantly thereafter. The majority of isolates expressed fHbp at a level associated with vaccine-induced protection. A wider age authorization for the vaccine may result in increased prevention of NmB disease.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127030"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25003275","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Invasive meningococcal disease, caused by Neisseria meningitidis, remains a significant health threat. This study examined the genetic diversity of serogroup B (NmB) organisms and assessed the potential coverage offered by the MenB-FHbp vaccine, licensed for individuals aged 10–25 years. NmB vaccines have not yet been incorporated into most routine immunization programs in Canada, with the exception of campaigns to deal with specific outbreaks and targeted vaccination efforts for at-risk groups.
Methods
From 2013 to 2020, NmB strains causing invasive meningococcal disease were collected through the Canadian Immunization Monitoring Program ACTive surveillance network. Each isolate underwent analysis to determine clonal complex (CC) and factor-H binding protein peptide (fHbp), and fHbp surface expression using the Meningococcal Antigen Surface Expression (MEASURE) assay.
Results
Of 119 isolates analyzed, 118 coded for full-length fHbp. CC-269 (48 isolates) and CC-41/44 (42 isolates) represented 75.6 % of all isolates. fHbp peptide 15 was the most prevalent peptide up until 2015 (47.4–53.9 %) but declined to 0–22.1 % afterwards. Median fHbp surface expression overall was 4270 MFI (IQR 2132–14,462). Peptides 15 and 210 (both CC-269) had the highest fHbp surface expression: peptide 15 (median: 18,446, IQR: 14,462–22,170) and peptide 210 (median: 28,306, IQR 24,935–31,678). Notably, 90.8 % of isolates had fHbp surface expression at a level associated with MenB-FHbp protection.
Conclusion
CC-269 and CC-41/44 predominated in 2013–2020. Notably, peptide 15, the most prevalent until 2015, declined significantly thereafter. The majority of isolates expressed fHbp at a level associated with vaccine-induced protection. A wider age authorization for the vaccine may result in increased prevention of NmB disease.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.